MedTrace Logo

CyberKnife Radiotherapy for the Treatment of Schwannomas: A Single-Center Retrospective Study

NCT07801560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-09-03

No results posted yet for this study

Summary

Historically, the management of schwannomas has relied primarily on observation, surgery, or conventional radiotherapy techniques. However, while surgery is curative, it carries significant risks-including postoperative complications, neurological deficits, and substantial morbidity-particularly for intracranial schwannomas located near critical neurovascular structures.

Stereotactic radiosurgery (SRS) has emerged as a less invasive alternative, offering remarkable precision in targeting tumor tissue while sparing adjacent healthy structures. This technique employs high doses of radiation focused precisely on the tumor, thereby controlling tumor growth with minimal morbidity. Several studies have demonstrated that SRS is particularly effective for small- to medium-sized schwannomas, yielding high tumor control rates (exceeding 90% at 5 years) while preserving neurological function. Despite this, the natural history, clinical data, and post-treatment outcomes associated with schwannomas remain incompletely understood or not fully elucidated in scientific literature.

Conditions

  • Schwannoma, Vestibular

Sponsors & Collaborators

  • Institut Rafael

    collaborator OTHER

  • Hartmann Oncology Radiotherapy Group, France

    lead OTHER

Principal Investigators

  • Nathaniel SCHER, M.D · Hartmann Oncology Radiotherapy Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2026-08-01
Completion
2026-08-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07801560 on ClinicalTrials.gov